EAST RUTHERFORD, N.J. — Cambrex has announced a significant $120 million investment to expand its U.S. operations, particularly focusing on its facility in Charles City. The company says this expansion aims to address the rising demand for API ( Active Pharmaceutical Ingredient) development and manufacturing, bolstering Cambrex's position in the peptide therapeutics market. Thomas Loewald, CEO of Cambrex, emphasized the importance of local API production for supply chain security. "Our customers, in partnership with federal and state agencies, are reshoring drug manufacturing in the U.S., the world’s largest pharmaceutical market," Loewald said. The investment will increase the Charles City site’s manufacturing capacity by 40%, reaching nearly one million liters. Thi

See Full Page